Annual Report for FY 2024-25
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eiko Lifesciences has filed its 48th Annual Report for FY 2024-25 ahead of the AGM scheduled on 5th September 2025 via video conferencing. On a consolidated basis, the company posted revenue from operations of ₹3,249.18 lakhs, up over 16% year-on-year, while profit after tax nearly doubled to ₹174.08 lakhs. EBITDA margin improved from 6.4% to 9.46%, reflecting better operational control. The company also expanded into container leasing and logistics through a subsidiary (over 800 TEU containers deployed) and launched Eiko Scientific Solutions LLP for specialty chemicals R&D. Key resolutions at the AGM include re-appointment of directors, approval of material related party transactions, increase in authorized share capital from ₹14 crore to ₹20 crore, and appointment of a new Whole-Time Director.
Shareholders should note the strong profit growth and EBITDA margin expansion as positives, while the increase in authorized share capital signals potential future fundraising. The material related party transaction resolution and appointment of a new Whole-Time Director are routine but worth monitoring for governance implications.